Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 19, 2006

Nastech Pharmaceutical's Intranasal Insulin Formulation Enters into Clinical Trial

  • Nastech Pharmaceutical initiated a Phase I pharmacokinetic study designed to evaluate the safety, bioavailability, and glucose response of Nastech’s rapid-acting intranasal insulin formulation. The study will compare Nastech’s intranasal formulation to an approved injectable product and to a recently approved new dosage form, Exubera® (insulin human [rDNA origin]) Inhalation Powder.

    Nastech believes its insulin nasal spray could provide patients with a convenient, needle-free alternative while avoiding possible pulmonary side effects or long-term toxicity associated with the inhalation of insulin.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »